Experienced in Hereditary Alpha-Tryptasemia

Cyrus Khandanpour

Ratzeburger Allee 160, 
Luebeck, SH, DE 
Experienced in Hereditary Alpha-Tryptasemia
Ratzeburger Allee 160, 
Luebeck, SH, DE 
OverviewLocationsClinical Research

Overview

Cyrus Khandanpour practices in Luebeck, Germany. Mr. Khandanpour is rated as an Experienced expert by MediFind in the treatment of Hereditary Alpha-Tryptasemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Multiple Myeloma, Leukemia, Myelodysplastic Syndrome (MDS), and Bone Marrow Transplant.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Ratzeburger Allee 160, Luebeck, SH 23538, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: TNB-383B
Study Phase: Phase 1/Phase 2
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial
Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Drug
Study Drugs: Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 2
View 1 Less Clinical Trial

83 Total Publications

A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma.
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma.
Journal: Frontiers in oncology
Published: May 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Khandanpour's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile